With the approval of Wegovy HD, Novo Nordisk joins Johnson & Johnson, Boehringer Ingelheim and USAntibiotics as beneficiaries of the FDA’s Commissioner’s National Priority Voucher program, which aims to review products that align with certain national priorities in less than two months.

The FDA approved a high-dose version of Novo Nordisk's blockbuster weight loss injection Wegovy, giving its go-ahead about two months faster than normal thanks to a voucher received from the commissioner's program.

Thursday's approval is ...

A high-dose version of Novo Nordisk’s injectable obesity drug Wegovy received U.S. approval.

In a sea of uncertainty, a large-scale, long-term Swedish study is the first to show that people using GLP-1 receptor agonists are less likely to have worsening mental illness. The study involved a national cohort of 95,490 people diagnosed with depression or anxiety disorder, who also were treated with any diabetes drug (apart from insulin).

Further weight loss details are yet to come this year, but Eli Lilly and Co. scored positive top-line results in Transcend-T2D-1, a phase III trial evaluating the efficacy and safety of retatrutide, an investigational first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist, as an adjunct to diet and exercise in type 2 diabetes (T2D).

Eli Lilly’s so-called triple-G reduced blood sugar levels in patients with type 2 diabetes by up to 1.9% in a late-stage trial — a slightly lower margin than Mounjaro achieved in its pivotal diabetes study.

The ...

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions.

Drugs such as semaglutide may be useful for mental health conditions associated with diabetes, authors sayDiabetes drugs could prevent anxiety and depression from worsening, according to research.Type 2 diabetes affects more than 800 million people globally and research shows that those with the condition are about twice as likely to have depression as the wider population. Continue reading...

GLP-1 medications used to treat diabetes and obesity were associated with a reduced need for hospital care and sickness absence due to psychiatric reasons, a new study shows. The large register-based study was carried out in collaboration between the University of Eastern Finland, Karolinska Institutet in Stockholm and Griffith University in Australia.

The study findings may spark treatment innovations for depression and anxiety.